SCHEMBL4584794

SCHEMBL4584794

CCCCCc1[c]c2cc3ccccc3cc2cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.38
NPC1 O15118 2/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 1/20 0.36
KCNH2 Q12809 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
CETP P11597 1/20 0.35
BCHE P06276 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2A6 P11509 1/20 0.34
EPHX1 P07099 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4585268 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL4585267 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL4584285 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL6439117 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL2252881 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL4585792 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL2256644 0.98 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL2254290 0.95 NPC1 (0.37) TLR8NPC1LMNARAB9ASMN1; SMN2
SCHEMBL4584654 0.88 CYP2A6 (0.37) NPC1RAB9AMEN1KMT2AATM
SCHEMBL360721 0.85 KCNH2 (0.39) TLR8NPC1LMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334391-B2 Functionalized heteroacenes XEROX CORPORATION (US) 2012-12-18 US claimed
US-7372071-B2 Functionalized heteroacenes and electronic devices generated therefrom XEROX CORPORATION (US) 2008-05-13 US claimed
US-20070260069-A1 Functionalized heteroacenes XEROX CORPORATION 2007-11-08 US claimed
US-20070235721-A1 Functionalized heteroacenes and electronic devices generated therefrom XEROX CORPORATION 2007-10-11 US claimed
US-20220069354-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2022-03-03 US disclosed
EP-3904337-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL FUJIFILM Wako Pure Chemical Corporation (JP) 2021-11-03 EP disclosed
CN-113166043-A Electrolyte for sulfur-based magnesium battery 富士胶片和光纯药株式会社 2021-07-23 CN disclosed
EP-3439097-B1 ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2020-12-30 EP disclosed
US-10727534-B2 Electrolyte solution containing magnesium ions FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2020-07-28 US disclosed
WO-2020138377-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL 富士フイルム和光純薬株式会社 2020-07-02 WO disclosed
US-20190131657-A1 ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-05-02 US disclosed
EP-3439097-A1 ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS FUJIFILM Wako Pure Chemical Corporation (JP) 2019-02-06 EP disclosed
EP-1843410-B1 Functionalized heteroacenes and electronic devices generated therefrom XEROX CORP (US) 2013-10-16 EP disclosed
EP-1843410-A2 Functionalized heteroacenes and electronic devices generated therefrom Xerox Corporation (US) 2007-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10727534-B2 Electrolyte solution containing magnesium ions MLX, PRDX1, PRDX6 TLR8 2468/4885NPC1 2092/4885LMNA 707/4885
US-20070260069-A1 Functionalized heteroacenes SOD1, AHR, NR0B2 TLR8 2241/4885NPC1 3578/4885LMNA 3010/4885
US-20220069354-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL SLC26A3, PRDX4, PRDX2 TLR8 4273/4885NPC1 3726/4885LMNA 4077/4885
US-20190131657-A1 ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS MLX, PRDX1, PRDX6 TLR8 2468/4885NPC1 2092/4885LMNA 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.